Our Promidian consultants bring you insight on some of today’s pressing industry issues.
Sell’n Gene Therapies: A Landscape Assessment of Cell and Gene Therapy Reimbursement
Cell and gene therapies hold great life-saving potential, with the ability to treat disease states with significant morbidity, mortality, or treatment-related complications. However, in addition to bringing substantial benefits to patients, many of these new therapies will bring steep price tags. In this article, we detail potential solutions to the novel financial challenges created by cell and gene therapies, including our thinking around how to enable broader access to these therapies through the utilization of shared payment pools.
PM360 Four Key Questions About Data Analytics
The future of data analytics will be nothing short of a revolution in the healthcare business model. As recently published in PM360, Promidian weighs in on how the process behind collecting and analyzing data is changing.
Harnessing Immuno-Oncology: Keys to Maximizing the Opportunity of Cancer Care’s New Frontier
The past decade has seen a major shift in immuno-oncology treatments. The approval of chimeric antigen receptor (CAR) T-cell therapies, along with several cell and gene therapies on the way, puts us at an inflection point of innovation in immuno-oncology. In this paper, we look at what sets immuno-oncology products apart from traditional oncology treatments. We also examine various ways manufacturers have responded and should respond to both the opportunities and challenges immuno-oncology therapies offer in order to successfully commercialize and realize the value of these assets.
How to Maximize the Value of New Advances in Oncology
The future of oncology care will be shaped by advancements that expand what is possible in terms of customer interactions, screening and diagnosis, and the development of targeted medicines. Based on Promidian’s keynote address at CBI’s 11th Annual Oncology Market Access Strategy Summit, this paper explores the forces driving technological advancements that will reshape oncology treatment in the very near future. We also examine two new technologies—one biotechnological and one digital—and identify the keys to maximizing the benefits of these technologies in order to ensure greater value for providers, patients, and manufacturers alike.
PharmaVoice The Radical Implications of Indication-Specific Pricing
A major change is under way that has the potential to impact the entire process of developing, pricing, and selling pharmaceuticals—the advent of indication-specific pricing. This paper provides context to this important change, highlights some of the implications about which biopharma companies should be aware, and leaves you with a framework for raising and addressing pertinent questions across the biopharma value chain.
Industry Issue Brief Buying into Biosimilars: An Analysis of US Payer Views on Biosimilar Products
As biosimilars enter the US market, payers hold enormous power to drive uptake, should they elect to employ preferential handling of biosimilars over the originator brands. Payers’ views on these new, potentially more cost-effective treatment alternatives should be top of mind for any manufacturer with a stake in this market. Through in-depth research with payers, Promidian has uncovered key decision-making factors and considerations of strategic value both for manufacturers looking to launch new biosimilar products as well as those preparing for biosimilar competition.
PharmaVoice Don’t Poke the Bear: The Effect of Pharmaceutical Pricing on Perception and Future Innovation
Aggressive pharmaceutical pricing strategies have recently grabbed headlines. Whether these strategies are justified or even successful is not the point. Rather, what is important is the negative public perception that significant price hikes create for the industry as a whole. In this climate, the industry needs to do a better job of talking about how prices are set and how that money is invested—otherwise we risk losing control of how we price our products and operate our businesses.
Pharmaceutical Executive Precision Medicine’s March to Market: “Pairing” for Success
With the recent wave of targeted therapy approvals and more biomarker-driven treatments on the horizon, properly commercializing biopharma drugs paired with a companion diagnostic can be a competitive differentiator. As recently published in Pharmaceutical Executive, Promidian experts offer four “can’t miss” strategies for successfully managing the development, launch, and commercialization of Rx-CDx pairings.
Pharmaceutical Executive Roundtable of Biopharma Industry Leaders Offers Insights on Market Access Challenges
Promidian participated in a feature roundtable hosted by Pharmaceutical Executive to discuss how market access dynamics are likely to evolve over the next few years and the implications of this evolution for biopharma companies. The magazine featured a recap of the highlights of the panel discussion.
A Review of the FDA’s Draft Guidance on Biosimilars
The Biologics Price Competition and Innovation Act of 2009—enacted in March 2010 as part of the Patient Protection and Affordable Care Act—laid the foundation for an abbreviated approval pathway for biosimilars in the United States. However, the healthcare reform legislation left specific details of the approval pathway for biosimilars to the discretion of the US Food and Drug Administration (FDA), including regulatory processes and clinical trial requirements. As a result, industry stakeholders have been eagerly awaiting additional guidance.
The Patient-Centered Medical Home: An Emerging Health Care Delivery Model
Fundamental changes are being implemented in the healthcare industry at an accelerated rate. It is critical that life sciences companies understand the trends and undercurrents of policy and practices being employed in order to succeed in these turbulent times. One key driver of these changes is the return to a primary care-driven model of care administration, delivered through the patient-centered medical home (PCMH).